Unlike tech giants, biotech companies face a "patent cliff." After about 20 years, their blockbuster drugs lose patent protection, and generic competition causes revenues to plummet by over 95%. This fundamental business model limitation prevents the sustained compounding required to reach mega-valuations.

To counter the inevitable patent expiration of its blockbuster drug Jakafi, Incyte's long-term strategy involved developing superior internal products to replace it. This approach aims to cannibalize its own revenue stream before competitors can.

To offset the impending 2027 patent loss for its blockbuster drug Xtandi, Astellas is not relying on a single successor. The company is betting on five distinct strategic brands across bladder cancer, AML, geographic atrophy, and women's health to collectively replace the revenue and mitigate the impact.

Large pharmaceutical companies face losing up to 50% of their revenues by 2030 due to the largest patent expiration wave in history. To survive, they will be forced to acquire innovation from the biotechnology sector, fueling a sustained M&A cycle for years to come.

Basilea commercializes its products through third-party partners in nearly 80 countries, rather than employing its own sales force. This lean model allows revenues from new country launches to grow without a corresponding increase in SG&A costs, directly boosting profitability and de-risking future patent expiries.

Western pharmaceutical giants face losing $400 billion in annual revenue as major drug patents expire. This forces them to urgently acquire new drug assets to fill the gap, making China's increasingly innovative, fast, and cost-effective biotech ecosystem a primary and necessary source for their future pipelines.

Unlike tech, the pharma business model is defined by a patent cliff. As blockbuster drugs go generic, companies must find entirely new ones to survive, forcing a complete business reinvention every 10-15 years—a fundamental flaw that deters long-term investors.

Widespread conservative 2026 guidance across biopharma is not driven by anticipated tariffs or policy changes. Instead, companies are finally feeling the direct impact of the long-discussed "patent cliff," with multiple major firms citing imminent losses of exclusivity (LOEs) for their blockbuster drugs as the primary headwind.

Despite shedding over 22,000 jobs, large pharmaceutical companies are aggressively investing in external assets. This counterintuitive trend is driven by the urgent need to fill revenue gaps from a looming $300 billion patent cliff, signaling a major strategic shift from internal R&D to external innovation acquisition.